Remove Clinical Development Remove Drugs Remove Immune Response
article thumbnail

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

The Pharma Data

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

article thumbnail

The potential of CD24 in cancer immunotherapy

Drug Target Review

Pheast Therapeutics is developing macrophage-focused immunotherapies to treat cancer. The company’s lead programme is targeting CD24, an immune inhibitory signal that is hijacked by cancer to suppress immune attack. How does CD24 contribute to immune evasion in ovarian cancer and triple-negative breast cancer?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A research team searches for every gene that helps tumors evade immunotherapy

Broad Institute

As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014. We wanted to see whether there were as yet undiscovered drug targets that would lead to amazing cancer immunotherapies,” Manguso said.

Research 137
article thumbnail

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

Preliminary blinded data on NVX-CoV2373 in older adults needed to proceed to Phase 3 has previously been positively reviewed by the Food and Drug Administration (FDA). Additional clinical data from the Phase 2 trial conducted in the U.S. and Australia are expected to be unblinded in Q1 and will be targeted for publication.

article thumbnail

Not all neoantigens are created equal

Drug Target Review

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response.

article thumbnail

Unveiling neoantigen-directed cancer treatment

Drug Target Review

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105
article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.